「ag」の検索結果
41件：21～25件目を表示
-
March 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
vative. BAC is widely used in eye drops but it is known to occasionally cause corneal epithelial damage1. Our goal was to develop a formulation that maintains the efficacy of the previous formulation ...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904_0.pdf -
vative. BAC is widely used in eye drops but it is known to occasionally cause corneal epithelial damage1. Our goal was to develop a formulation that maintains the efficacy of the previous formulation ...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904.pdf -
お知らせ | 千寿製薬株式会社
BAC-free formulation of Aibeta® combination eye drops（PDF） March 7, 2025 Announcement of Licensing Agreement with Brill International（PDF） February 20, 2025 Launch and Distribution of “MIEr for Beeli...
http://www.senju.co.jp/english/news/ -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
4日～2025年9月17日 開催地：Athens, GREECE Summary of nonclinical toxicity evaluation of SJP-0132, a TRPV1 antagonist Satoko Doi1, Satomi Kikuchi2, Yoshihisa Nakano2, Shigeki Matsumoto2, Yoshinori Yamagiwa1, Ko...
http://www.senju.co.jp/english/rd/society/